Cardiovascular and Metabolic Diseases
AstraZeneca’s (AZN) Cardiovascular and Metabolic Diseases (or CVMD) segment includes Brilinta, Bydureon, Byetta, Farxiga, Onglyza, and Symlin. It also includes legacy products Atacand, Crestor, and Seloken.
The above chart shows revenues for key products in the CVMD segment over the last few quarters. For 3Q17, the segment’s revenues fell 4% at constant exchange rates to ~$1.8 billion due to lower sales of Onglyza, Bydureon, Crestor, and Seloken, substantially offset by the strong performances of Brilinta, Farxiga, and Atacand.
Brilinta is one of AstraZeneca’s new CVMD products classified in its growth platform. The drug reported 36% growth in revenues at constant exchange rates to $284 million, while foreign exchange impacted its revenues positively by 1% during 3Q17. US markets contributed ~50% of total Brilinta sales and reported 67% growth in revenues to $140 million. European markets reported 12% growth in revenues at constant exchange rates to $78 million during 3Q17, while emerging markets reported 20% growth in revenues at constant exchange rates to $54 million.
Farxiga reported 29% growth in revenues at constant exchange rates to $285 million, while foreign exchange impacted it positively by 1% during 3Q17. Revenue growth was driven by strong sales of Farxiga across all regions, including the United States, European markets, emerging markets, and the rest of the world.
Crestor is AstraZeneca’s largest selling CVMD product. It reported a 14% fall in revenues at constant exchange rates to $580 million during 3Q17, driven by lower sales in US and European markets, partially offset by growth in emerging markets.
Other CVMD products
Other products in the CVMD segment include Atacand, Bydureon, Byetta, Onglyza, and Seloken. Of those drugs, Atacand reported an 11% growth in revenues at constant exchange rates to $80 million during 3Q17. The other drugs reported lower sales across all regions except emerging markets.
The Vanguard FTSE Europe ETF (VGK) holds 12.3% of its total assets in the healthcare sector. VGK holds 0.8% in AstraZeneca (AZN), 1.9% in Novartis (NVS), 1% in Sanofi (SNY), and 0.9% in GlaxoSmithKline (GSK).